Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13049083 | 1.00 | FOLH1 (0.57) | FOLH1SLC6A5CPB2GSRRNPEP | |
| SCHEMBL7165072 | 0.95 | FOLH1 (0.50) | FOLH1SLC6A5CPB2GSRCA1 | |
| SCHEMBL7165076 | 0.95 | FOLH1 (0.50) | FOLH1SLC6A5CPB2GSRCA1 | |
| SCHEMBL7165075 | 0.95 | FOLH1 (0.50) | FOLH1SLC6A5CPB2GSRCA1 | |
| SCHEMBL29918590 | 0.88 | FOLH1 (0.55) | FOLH1SLC6A5CPB2GSRRNPEP | |
| SCHEMBL18741276 | 0.88 | FOLH1 (0.55) | FOLH1SLC6A5CPB2GSRRNPEP | |
| SCHEMBL18741275 | 0.88 | FOLH1 (0.55) | FOLH1SLC6A5CPB2GSRRNPEP | |
| SCHEMBL18876678 | 0.87 | NOD1 (0.46) | FOLH1 | |
| SCHEMBL22689972 | 0.87 | FOLH1 (0.54) | FOLH1SLC6A5CPB2GSRCA1 | |
| SCHEMBL22689833 | 0.87 | FOLH1 (0.54) | FOLH1SLC6A5CPB2GSRRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148418-A1 | TYROSINASE ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2023-05-11 | — | — | US | claimed |
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-05-03 | — | — | US | claimed |
| US-12624068-B2 | Exon skipping by peptide nucleic acid derivatives | OLIPASS CORPORATION (KR) | 2026-05-12 | — | — | US | disclosed |
| CN-117510576-A | Method for preparing palmitoyl tripeptide-38 | 富乐马鸿凯（大连）医药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-110831958-B | Tyrosinase antisense oligonucleotides | 奥利通公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230148418-A1 | TYROSINASE ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2023-05-11 | — | — | US | disclosed |
| CN-110248956-B | HIF-1 alpha antisense oligonucleotides | 奥利通公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | HIF1A, HIF1AN, UPF1 | FOLH1 890/4885SLC6A5 4551/4885CPB2 3556/4885 |
| US-12624068-B2 | Exon skipping by peptide nucleic acid derivatives | NSUN2, NSUN3, UPF1 | FOLH1 1261/4885SLC6A5 2069/4885CPB2 2221/4885 |
| US-20230148418-A1 | TYROSINASE ANTISENSE OLIGONUCLEOTIDES | TYR, POLR1C, RNGTT | FOLH1 192/4885SLC6A5 4052/4885CPB2 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.